Factor XIII (human)

DB12909ApprovedInvestigationalProtein Based TherapiesBlood Coagulation Factors Hemostatics

Factor XIII (human) is a purified form of Factor XIII that is used to prevent and treat surgical bleeding in patients with a Factor XIII deficiency. Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade.

Mechanism: Also known as Fibrin Stabilizing Factor (FSF), Factor XIII is an endogenously produced coagulation factor and the final enzyme within the blood coagulation cascade. Within the body, FXIII circulates as a heterotetramer composed of 2 A-subunits and 2 B-subunits (A2B2). When activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. As a result, the active transglutaminase from subunit A cross-links fibrin and other proteins resulting in increased mechanical strength and resistance to fibrinolysis of the fibrin clot. This contributes to enhanced platelet and clot adhesion to injured tissue, thereby improving blood coagulation and maintenance of hemostasis. Exogenous replacement of Factor XIII is a cornerstone of treatment for bleeding associated with congenital Factor XIII deficiency.
Curator reviewed · 2 references
Primary indication: Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital...Curator reviewed · 2 structured indications
First approval: Canada, 2013 · United States, 2011
Also known as: Coagulation factor XIII, recombinant · Factor XIII · Factor XIII (fibrin stabilising factor) · Factor XIII concentrate (human) · Factor XIII, human
Brand names: Corifact